This result suggests that the variable sensitivity of different tumor lineages to HER2-directed therapies as reported in a recent basket trial36, is likely due, at least in part, to differences among cancers in their dependence on HER2 signaling for tumor growth and survival. Here, ERBB2 is linked to cancer.